Cellectis shares rise 10.87% intraday after non-viral gene editing study published in Nature Communications.

Cellectis surged 10.87% intraday following the publication of a Nature Communications article on its non-viral gene editing process for hematopoietic stem cells, demonstrating efficient gene insertion. This development, highlighted by GlobeNewswire, underscores the company’s progress in advancing its gene-editing platform, likely attracting investor optimism. Additionally, a recent collaboration with Moligo Technologies, also reported in Nature Communications, showcased the potential of enzymatic single-stranded DNA for non-viral gene editing, further reinforcing Cellectis’s technological edge. These scientific milestones align with the stock’s sharp intraday rise, as they position the company as a leader in innovative gene therapy solutions.